Therefore, the tumor expression of PDL-1 (tPDL-1) is currently the only biomarker to guide the therapeutic choice, but with low efficiency, highlighting the need to identify new biomarkers to improve the efficacy of the well-consolidated tPDL1. The gene discussed is CD274; the disease is neoplasm.